Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer

Table 3

Univariate analysis of clinical features and the curative effect of 33 advanced colorectal cancer patients (n = 33).

Characteristics		Total, no.	Effective, no. (%)
Sex	Male	15	9 (60)	0.323
	Female	18	7 (38.89)
Age	<55 years	17	8 (47.06)	0.971
	≥55 years	16	8 (50)
ECOG	0	10	8 (80)	0.034
	1	23	8 (34.78)
Primary tumor location	Left	23	9 (39.13)	0.164
	Right	10	7 (70)
Liver metastases	Yes	20	10 (50)	0.782
	No	13	6 (46.15)
Lung metastases	Yes	28	11 (39.29)	0.032
	No	5	5 (100)
Lymph node metastasis	Yes	22	12 (54.55)	0.286
	No	11	4 (36.36)
Excision of primary lesion	Yes	29	15 (51.72)	0.181
	No	4	1 (25)
Raltitrexed	Yes	12	4 (33.33)	0.2
	No	21	12 (57.14)
Bevacizumab	Yes	28	11 (39.29)	0.034
	No	5	5 (100)
Cetuximab	Yes	11	4 (6.36)	0.101
	No	22	12 (54.55)
Number of previous chemotherapy lines	2 line	16	12 (75)	0.005
	3 lines or above	17	4 (23.53)
Regorafenib	80 mg	23	10 (43.48)	0.456
	120 mg	10	6 (60)
KRAS	Mutation	8	5 (62.5)	0.203
	Wild	13	4 (30.77)

ECOG, Eastern Cooperative Oncology Group performance status.